keyword
https://read.qxmd.com/read/38701539/mesenchymal-stem-cell-derived-exosomes-for-management-of-prostate-cancer-an-updated-view
#1
REVIEW
Fahimeh Lavi Arab, Akram Hoseinzadeh, Fatemeh Hafizi, Fatemeh Sadat Mohammadi, Farid Zeynali, Melika Hadad Tehran, Amirreza Rostami
Prostate cancer represents the second most prevalent form of cancer found in males, and stands as the fifth primary contributor to cancer-induced mortality on a global scale. Research has shown that transplanted mesenchymal stem cells (MSCs) can migrate by homing to tumor sites in the body. In prostate cancer, researchers have explored the fact that MSC-based therapies (including genetically modified delivery vehicles or vectors) and MSC-derived exosomes are emerging as attractive options to improve the efficacy and safety of traditional cancer therapies...
May 2, 2024: International Immunopharmacology
https://read.qxmd.com/read/38701533/elisa-assay-for-the-quantification-of-ipilimumab-in-human-serum-plasma-milk-and-cerebrospinal-fluid
#2
JOURNAL ARTICLE
Dick Pluim, Pauline Buitelaar, Karen A M de Jong, Hilde Rosing, Dieta Brandsma, Alwin D R Huitema, Jos H Beijnen
Ipilimumab is an immune checkpoint inhibitor of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Ipilimumab has become part of the standard of care for different types of cancer. The efficacy of these treatments is limited due to immune-related toxicity and high economic costs. Dose rationalization studies based on pharmacokinetic data may help to address these limitations. For this purpose, more sensitive analytical methods are needed. We report the development and validation of the first enzyme-linked immunosorbent assay (ELISA) for sensitive determination of ipilimumab concentrations in human serum, plasma, cerebrospinal fluid (CSF), and milk...
April 8, 2024: Journal of Pharmaceutical and Biomedical Analysis
https://read.qxmd.com/read/38701516/photochemistry-of-ru-ii-triazole-complexes-with-6-membered-chelate-ligands-detection-and-reactivity-of-ligand-loss-intermediates
#3
JOURNAL ARTICLE
Katie Eastham, Aaron D W Kennedy, Synøve Ø Scottwell, Jack E Bramham, Samantha Hardman, Alexander P Golovanov, Paul A Scattergood, James D Crowley, Paul I P Elliott
Photochemical ligand release from metal complexes may be exploited in the development of novel photoactivated chemotherapy agents for the treatment of cancer and other diseases. Highly intriguing photochemical behavior is reported for two ruthenium(II) complexes bearing conformationally flexible 1,2,3-triazole-based ligands incorporating a methylene spacer to form 6-membered chelate rings. [Ru(bpy)2 (pictz)]2+ ( 1 ) and [Ru(bpy)2 (btzm)]2+ ( 2 ) (bpy = 2,2'-bipyridyl; pictz = 1-(picolyl)-4-phenyl-1,2,3-triazole; btzm = bis(4-phenyl-1,2,3-triazol-4-yl)methane) exhibit coordination by the triazole ring through the less basic N2 atom as a consequence of chelation and readily undergo photochemical release of the pictz and btzm ligands (ϕ = 0...
May 3, 2024: Inorganic Chemistry
https://read.qxmd.com/read/38701508/a-review-targeting-ubr5-domains-to-mediate-emerging-roles-and-mechanisms-chance-or-necessity
#4
JOURNAL ARTICLE
Yizhu Wang, Kaiyi Niu, Yanlong Shi, Feilong Zhou, Xinhao Li, Yunxin Li, Tianyi Chen, Yewei Zhang
Ubiquitinases are known to catalyze ubiquitin chains on target proteins to regulate various physiological functions like cell proliferation, autophagy, apoptosis, and cell cycle progression. As a member of E3 ligase, ubiquitin protein ligase E3 component n-recognin 5 (UBR5) belongs to the HECT E3 ligase and has been reported to be correlated with various pathophysiological processes. In this review, we give a comprehensive insight into the structure and function of UBR5. We discuss the specific domains of UBR5 and explore their biological functions separately...
May 3, 2024: International Journal of Surgery
https://read.qxmd.com/read/38701503/an-international-expert-based-consensus-on-the-definition-of-a-clinical-near-complete-response-after-neoadjuvant-chemo-radiotherapy-for-rectal-cancer
#5
JOURNAL ARTICLE
Petra A Custers, Geerard L Beets, Simon P Bach, Lennart K Blomqvist, Nuno Figueiredo, Marc J Gollub, Anna Martling, Jarno Melenhorst, Cinthia D Ortega, Rodrigo O Perez, J Joshua Smith, Doenja M J Lambregts, Regina G H Beets-Tan, Monique Maas
BACKGROUND: A variety of definitions for a clinical near-complete response after neoadjuvant (chemo) radiotherapy for rectal cancer are currently used. This variety leads to inconsistency in clinical practice, long-term outcome, and trial enrollment. OBJECTIVE: The aim of this study was to reach expert-based consensus on the definition of a clinical near-complete response after (chemo) radiotherapy. DESIGN: A modified Delphi process, including a systematic review, 3 surveys, and 2 meetings, was performed with an international expert panel consisting of 7 surgeons and 4 radiologists...
June 1, 2024: Diseases of the Colon and Rectum
https://read.qxmd.com/read/38701500/association-of-glucagon-like-peptide-1-receptor-agonists-with-risk-of-cancers-evidence-from-a-drug-target-mendelian-randomization-and-clinical-trials
#6
JOURNAL ARTICLE
Yuming Sun, Yongjia Liu, Yating Dian, Furong Zeng, Guangtong Deng, Shaorong Lei
BACKGROUND: Glucagon-like peptide-1 receptor (GLP1R) agonists have been approved by Food and Drug Administration for management of obesity. However, the causal relationship of GLP1R agonists (GLP1RA) with cancers still unclear. METHODS: The available cis-eQTLs for drugs target genes (GLP1R) were used as proxies for exposure to GLP1RA. Mendelian randomizations (MR) were performed to reveal the association of genetically-proxied GLP1RA with 14 common types cancer from large-scale consortia...
May 3, 2024: International Journal of Surgery
https://read.qxmd.com/read/38701496/a-commentary-on-circulating-metabolic-markers-after-surgery-identify-patients-at-risk-for-severe-postoperative-complications-a-prospective-cohort-study-in-colorectal-cancers
#7
JOURNAL ARTICLE
Yajie Wang, Huan Deng, Yisheng Pan
No abstract text is available yet for this article.
May 3, 2024: International Journal of Surgery
https://read.qxmd.com/read/38701438/diet-modulates-the-gut-microbiome-metabolism-and-mammary-gland-inflammation-to-influence-breast-cancer-risk
#8
JOURNAL ARTICLE
Alana A Arnone, Adam S Wilson, David R Soto-Pantoja, Katherine L Cook
Several studies have indicated a strong link between obesity and the risk of breast cancer. Obesity decreases gut microbial biodiversity and modulates Bacteroidetes-to-Firmicutes proportional abundance, suggesting that increased energy-harvesting capacity from indigestible dietary fibers and elevated lipopolysaccharide bioavailability may promote inflammation. To address the limited evidence linking diet-mediated changes in the gut microbiota to breast cancer risk, we aimed to determine how diet affects the microbiome and breast cancer risk...
May 3, 2024: Cancer Prevention Research
https://read.qxmd.com/read/38701435/effect-of-clonal-hematopoiesis-mutations-and-canakinumab-treatment-on-incidence-of-solid-tumors-in-the-cantos-randomized-clinical-trial
#9
JOURNAL ARTICLE
Janghee Woo, Tingting Zhai, Fang Yang, Huilei Xu, Margaret L Healey, Denise P Yates, Michael T Beste, David P Steensma
Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The most common CH mutations occur in the DNMT3A and TET2 genes and result in increased pro-inflammatory signaling. The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS, NCT01327846) evaluated the neutralizing anti-IL-1β antibody canakinumab in 10,061 randomized patients with a history of myocardial infarction and persistent inflammation; DNA samples were available from 3,923 patients for targeted genomic sequencing...
May 3, 2024: Cancer Prevention Research
https://read.qxmd.com/read/38701434/the-invisible-co-afflicted-caregivers-of-rectal-cancer-survivors
#10
JOURNAL ARTICLE
Qi Chen, Sally You, Srinivas J Ivatury
No abstract text is available yet for this article.
May 3, 2024: Diseases of the Colon and Rectum
https://read.qxmd.com/read/38701433/interrater-agreement-of-height-assessment-by-rigid-proctoscopy-rectoscopy-for-rectal-carcinoma
#11
JOURNAL ARTICLE
Matthias J Kraemer, Sarkhan Nabiyev, Silvia E Kraemer, Stephanie Schipmann
BACKGROUND: Some guidelines for rectal carcinoma consider 12 cm, measured by rigid endoscopy to be the cutoff tumor height for optional neoadjuvant chemoradiation. Measuring differences of only a few centimeters may therefore predetermine choice of further therapy. However, rigid endoscopy may exhibit similar operator dependence as do most other clinical examination methods. OBJECTIVES: Evaluation of concordance of rigid rectoscopic tumor height measurements performed by 4 experienced examiners, 2 in lithotomy and 2 in left lateral position...
May 3, 2024: Diseases of the Colon and Rectum
https://read.qxmd.com/read/38701421/spatialcells-automated-profiling-of-tumor-microenvironments-with-spatially-resolved-multiplexed-single-cell-data
#12
JOURNAL ARTICLE
Guihong Wan, Zoltan Maliga, Boshen Yan, Tuulia Vallius, Yingxiao Shi, Sara Khattab, Crystal Chang, Ajit J Nirmal, Kun-Hsing Yu, David Liu, Christine G Lian, Mia S DeSimone, Peter K Sorger, Yevgeniy R Semenov
Cancer is a complex cellular ecosystem where malignant cells coexist and interact with immune, stromal and other cells within the tumor microenvironment (TME). Recent technological advancements in spatially resolved multiplexed imaging at single-cell resolution have led to the generation of large-scale and high-dimensional datasets from biological specimens. This underscores the necessity for automated methodologies that can effectively characterize molecular, cellular and spatial properties of TMEs for various malignancies...
March 27, 2024: Briefings in Bioinformatics
https://read.qxmd.com/read/38701414/metabolic-models-predict-fotemustine-and-the-combination-of-eflornithine-rifamycin-and-adapalene-cannabidiol-for-the-treatment-of-gliomas
#13
JOURNAL ARTICLE
Ali Kishk, Maria Pires Pacheco, Tony Heurtaux, Thomas Sauter
Gliomas are the most common type of malignant brain tumors, with glioblastoma multiforme (GBM) having a median survival of 15 months due to drug resistance and relapse. The treatment of gliomas relies on surgery, radiotherapy and chemotherapy. Only 12 anti-brain tumor chemotherapies (AntiBCs), mostly alkylating agents, have been approved so far. Glioma subtype-specific metabolic models were reconstructed to simulate metabolite exchanges, in silico knockouts and the prediction of drug and drug combinations for all three subtypes...
March 27, 2024: Briefings in Bioinformatics
https://read.qxmd.com/read/38701411/ai-identifies-potent-inducers-of-breast-cancer-stem-cell-differentiation-based-on-adversarial-learning-from-gene-expression-data
#14
JOURNAL ARTICLE
Zhongxiao Li, Antonella Napolitano, Monica Fedele, Xin Gao, Francesco Napolitano
Cancer stem cells (CSCs) are a subpopulation of cancer cells within tumors that exhibit stem-like properties and represent a potentially effective therapeutic target toward long-term remission by means of differentiation induction. By leveraging an artificial intelligence approach solely based on transcriptomics data, this study scored a large library of small molecules based on their predicted ability to induce differentiation in stem-like cells. In particular, a deep neural network model was trained using publicly available single-cell RNA-Seq data obtained from untreated human-induced pluripotent stem cells at various differentiation stages and subsequently utilized to screen drug-induced gene expression profiles from the Library of Integrated Network-based Cellular Signatures (LINCS) database...
March 27, 2024: Briefings in Bioinformatics
https://read.qxmd.com/read/38701369/metabolic-reprogramming-of-tumor-associated-macrophages-using-glutamine-antagonist-jhu083-drives-tumor-immunity-in-myeloid-rich-prostate-and-bladder-cancer-tumors
#15
JOURNAL ARTICLE
Monali Praharaj, Fan Shen, Alex J Lee, Liang Zhao, Thomas R Nirschl, Debebe Theodros, Alok K Singh, Xiaoxu Wang, Kenneth M Adusei, Kara A Lombardo, Raekwon A Williams, Laura A Sena, Elizabeth A Thompson, Ada Tam, Srinivasan Yegnasubramanian, Edward J Pearce, Robert D Leone, Jesse Alt, Rana Rais, Barbara S Slusher, Drew M Pardoll, Jonathan D Powell, Jelani C Zarif
Glutamine metabolism in tumor microenvironments critically regulates anti-tumor immunity. Using glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes (TIMs). We show JHU083-mediated glutamine antagonism in tumor microenvironments induces TNF, pro-inflammatory, and mTORC1 signaling in intratumoral TAM clusters. JHU083-reprogrammed TAMs also exhibit increased tumor cell phagocytosis and diminished pro-angiogenic capacities...
May 3, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38701364/sequencing-considerations-in-the-third-line-treatment-of-metastatic-colorectal-cancer
#16
JOURNAL ARTICLE
Afsaneh Barzi, Tanios Bekaii-Saab
Numerous advances in the standard of care for metastatic colorectal cancer (mCRC), including the approval of several new treatments indicated for treatment in the third line or later (3L+), have been made, yet data and appropriate guidance on the optimal sequencing and treatment strategies for these lines of therapy are lacking. Four treatments-regorafenib, trifluridine/tipiracil alone or with bevacizumab, and fruquintinib-are FDA-approved and recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of mCRC in the 3L+...
May 2024: American Journal of Managed Care
https://read.qxmd.com/read/38701363/a-decade-of-progress-advances-in-the-third-line-treatment-of-patients-with-metastatic-colorectal-cancer
#17
REVIEW
Tanios Bekaii-Saab
The treatment of metastatic colorectal cancer (mCRC) remains challenging. There has been substantial progress in understanding the molecular pathology of the disease that has led to meaningful advancements in treatment options with varying mechanisms of action, although treatment remains costly. Cytotoxic therapies, which are typically combined with targeted therapies, remain the mainstay of first- and second-line treatment for mCRC. While also relevant in earlier lines of therapy, molecular testing has become increasingly important to guide therapy across lines of therapy, for which treatment options are limited...
May 2024: American Journal of Managed Care
https://read.qxmd.com/read/38701361/targeted-drug-delivery-by-mmae-farnesyl-bioconjugated-multivalent-chemically-self-assembled-nanorings-induces-potent-receptor-dependent-immunogenic-cell-death
#18
JOURNAL ARTICLE
Yiao Wang, Ozgun Kilic, Lakmal Rozumalski, Mark D Distefano, Carston R Wagner
Antibody-drug conjugates, nanoparticles, and liposomes have been used for anticancer drug delivery. The success of targeted killing of cancer cells relies heavily on the selectivity of the drug delivery systems. In most systems, antibodies or their fragments were used as targeting ligands. In this study, we have investigated the potential for protein-based octomeric chemically self-assembled nanorings (CSANs) to be used for anticancer drug delivery. The CSANs are composed of a DHFR-DHFR fusion protein incorporating an EGFR-targeting fibronectin and the anticancer drug MMAE conjugated through a C-terminal farnesyl azide...
May 3, 2024: Bioconjugate Chemistry
https://read.qxmd.com/read/38701358/cost-effectiveness-of-genetic-testing-of-endocrine-tumor-patients-using-a-comprehensive-hereditary-cancer-gene-panel
#19
JOURNAL ARTICLE
Attila Patócs, Petra Nagy, János Papp, Anikó Bozsik, Bálint Antal, Vince Kornél Grolmusz, Tímea Pócza, Henriett Butz
INTRODUCTION: Heterogenous clinical manifestations, overlapping phenotypes and complex genetic backgrounds are common in patients with endocrine tumors. There are no comprehensive recommendations for genetic testing and counselling of these patients compared to other hereditary cancer syndromes. The application of multigene panel testing is common in clinical genetic laboratories, but their performance for patients with endocrine tumors has not been assessed. METHODS: As a national reference center, we prospectively tested the diagnostic utility and cost-efficiency of a multigene panel covering 113 genes representing genetic susceptibility for solid tumors...
May 3, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38701350/venetoclax-a-new-player-in-the-treatment-of-children-with-high-risk-myeloid-malignancies
#20
JOURNAL ARTICLE
Riccardo Masetti, Francesco Baccelli, Davide Leardini, Franco Locatelli
Venetoclax selectively inhibits BCL-2 and restores apoptotic signaling of hematological malignant cells. Venetoclax in combination with hypomethylating and low-dose cytotoxic agents has revolutionized the management of elderly patients affected by acute myeloid leukemia (AML), as well as that of patients unfit to receive intensive chemotherapy. In a single phase 1 pediatric trial conducted on relapsed/refractory AML, the combination of venetoclax with intensive chemotherapy was shown to be safe and yielded promising response rates...
May 3, 2024: Blood Advances
keyword
keyword
159210
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.